|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deng C, Wu SG and Tian Y: Lung large cell
neuroendocrine carcinoma: An analysis of patients from the
surveillance, epidemiology, and End-Results (SEER) database. Med
Sci Monit. 25:3636–3646. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fasano M, Della Corte CM, Papaccio F,
Ciardiello F and Morgillo F: Pulmonary large-cell neuroendocrine
carcinoma: From epidemiology to therapy. J Thorac Oncol.
10:1133–1141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kinslow CJ, May MS, Saqi A, Shu CA,
Chaudhary KR, Wang TJC and Cheng SK: Large-Cell neuroendocrine
carcinoma of the lung: A population-based study. Clin Lung Cancer.
21:e99–e113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Derks JL, Hendriks LE, Buikhuisen WA,
Groen HJ, Thunnissen E, van Suylen RJ, Houben R, Damhuis RA, Speel
EJ and Dingemans AM: Clinical features of large cell neuroendocrine
carcinoma: A population-based overview. Eur Respir J. 47:615–624.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fisseler-Eckhoff A and Demes M:
Neuroendocrine tumors of the lung. Cancers (Basel). 4:777–798.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iyoda A, Hiroshima K, Moriya Y, Iwadate Y,
Takiguchi Y, Uno T, Nakatani Y and Yoshino I: Postoperative
recurrence and the role of adjuvant chemotherapy in patients with
pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc
Surg. 138:446–453. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Raez LE, Cassileth PA, Schlesselman JJ,
Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA and Podack ER:
Allogeneic vaccination with a B7.1 HLA-A gene-modified
adenocarcinoma cell line in patients with advanced non-small-cell
lung cancer. J Clin Oncol. 22:2800–2807. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lahiri A, Maji A, Potdar PD, Singh N,
Parikh P, Bisht B, Mukherjee A and Paul MK: Lung cancer
immunotherapy: Progress, pitfalls, and promises. Mol Cancer.
22:402023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Steven A, Fisher SA and Robinson BW:
Immunotherapy for lung cancer. Respirology. 21:821–833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M,
et al: NCCN Guidelines® Insights: Non-Small cell lung
cancer, version 2.2023. J Natl Compr Canc Netw. 21:340–350. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Travis WD: Advances in neuroendocrine lung
tumors. Ann Oncol. 21 (Suppl 7):vii65–vii71. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Asamura H, Kameya T, Matsuno Y, Noguchi M,
Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, et al:
Neuroendocrine neoplasms of the lung: A prognostic spectrum. J Clin
Oncol. 24:70–76. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nicholson AG, Tsao MS, Beasley MB, Borczuk
AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S,
et al: The 2021 WHO classification of lung tumors: Impact of
advances since 2015. J Thorac Oncol. 17:362–387. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kupeli M and Koseoglu RD: Large cell
carcinoma with adenocarcinoma in lung. J Coll Physicians Surg Pak.
28:240–242. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Welter S, Aigner C and Roesel C: The role
of surgery in high grade neuroendocrine tumours of the lung. J
Thorac Dis. 9 (Suppl 15):S1474–S1483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eichhorn F, Dienemann H, Muley T, Warth A
and Hoffmann H: Predictors of survival after operation among
patients with large cell neuroendocrine carcinoma of the lung. Ann
Thorac Surg. 99:983–989. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iyoda A, Hiroshima K, Toyozaki T, Haga Y,
Fujisawa T and Ohwada H: Clinical characterization of pulmonary
large cell neuroendocrine carcinoma and large cell carcinoma with
neuroendocrine morphology. Cancer. 91:1992–2000. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Travis WD: Pathology and diagnosis of
neuroendocrine tumors: Lung neuroendocrine. Thorac Surg Clin.
24:257–266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peifer M, Fernandez-Cuesta L, Sos ML,
George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander
T, et al: Integrative genome analyses identify key somatic driver
mutations of small-cell lung cancer. Nat Genet. 44:1104–1110. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang L, Fan Y and Lu H: Pulmonary large
cell neuroendocrine carcinoma. Pathol Oncol Res. 28:16107302022.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sturm N, Lantuejoul S, Laverriere MH,
Papotti M, Brichon PY, Brambilla C and Brambilla E: Thyroid
transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12)
expression in basaloid and large-cell neuroendocrine carcinomas of
the lung. Hum Pathol. 32:918–925. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu C, Qin Q and Cong H: Research progress
on the relationship between mitochondrial deoxyguanosine kinase and
apoptosis and autophagy in lung adenocarcinoma cells. Cancer
Insight. 1:53–62. 2022. View Article : Google Scholar
|
|
24
|
Carbone DP, Reck M, Paz-Ares L, Creelan B,
Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F,
et al: First-Line nivolumab in Stage IV or recurrent Non-Small-Cell
lung cancer. N Engl J Med. 376:2415–2426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun LY, Cen WJ, Tang WT, Long YK, Yang XH,
Ji XM, Yang JJ, Zhang RJ, Wang F, Shao JY, et al: Smoking status
combined with tumor mutational burden as a prognosis predictor for
combination immune checkpoint inhibitor therapy in non-small cell
lung cancer. Cancer Med. 10:6610–6617. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Garassino MC, Gelibter AJ, Grossi F,
Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L,
Bengala C, et al: Italian nivolumab expanded access program in
nonsquamous non-Small cell lung cancer patients: Results in
Never-Smokers and EGFR-mutant patients. J Thorac Oncol.
13:1146–1155. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iyoda A, Makino T, Koezuka S, Otsuka H and
Hata Y: Treatment options for patients with large cell
neuroendocrine carcinoma of the lung. Gen Thorac Cardiovasc Surg.
62:351–356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yoshida A, Kobayashi E, Kubo T, Kodaira M,
Motoi T, Motoi N, Yonemori K, Ohe Y, Watanabe SI, Kawai A, et al:
Clinicopathological and molecular characterization of
SMARCA4-deficient thoracic sarcomas with comparison to potentially
related entities. Mod Pathol. 30:797–809. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sarkaria IS, Iyoda A, Roh MS, Sica G, Kuk
D, Sima CS, Pietanza MC, Park BJ, Travis WD and Rusch VW:
Neoadjuvant and adjuvant chemotherapy in resected pulmonary large
cell neuroendocrine carcinomas: A single institution experience.
Ann Thorac Surg. 92:1180–1187. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tokito T, Kenmotsu H, Watanabe R, Ito I,
Shukuya T, Ono A, Nakamura Y, Tsuya A, Naito T, Murakami H, et al:
Comparison of chemotherapeutic efficacy between LCNEC diagnosed
using large specimens and possible LCNEC diagnosed using small
biopsy specimens. Int J Clin Oncol. 19:63–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim
HK, Choi YS, Han J, Kim J, Kwon OJ, et al: Chemotherapy for
pulmonary large cell neuroendocrine carcinoma: Similar to that for
small cell lung cancer or non-small cell lung cancer? Lung Cancer.
77:365–370. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shah MH, Goldner WS, Benson AB, Bergsland
E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, et
al: Neuroendocrine and adrenal tumors, version 2.2021, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
19:839–868. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
De Pas TM, Giovannini M, Manzotti M,
Trifiro G, Toffalorio F, Catania C, Spaggiari L, Labianca R and
Barberis M: Large-cell neuroendocrine carcinoma of the lung
harboring EGFR mutation and responding to gefitinib. J Clin Oncol.
29:e819–e822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
George J, Walter V, Peifer M, Alexandrov
LB, Seidel D, Leenders F, Maas L, Muller C, Dahmen I, Delhomme TM,
et al: Integrative genomic profiling of large-cell neuroendocrine
carcinomas reveals distinct subtypes of high-grade neuroendocrine
lung tumors. Nat Commun. 9:10482018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Peters S, Camidge DR, Shaw AT, Gadgeel S,
Ahn JS, Kim DW, Ou SI, Perol M, Dziadziuszko R, Rosell R, et al:
Alectinib versus Crizotinib in untreated ALK-positive
non-small-cell lung cancer. N Engl J Med. 377:829–838. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hayashi N, Fujita A, Saikai T, Takabatake
H, Sotoshiro M, Sekine K and Kawana A: Large cell neuroendocrine
carcinoma harboring an anaplastic lymphoma kinase (ALK)
rearrangement with response to alectinib. Intern Med. 57:713–716.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Iyoda A, Travis WD, Sarkaria IS, Jiang SX,
Amano H, Sato Y, Saegusa M, Rusch VW and Satoh Y: Expression
profiling and identification of potential molecular targets for
therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Ther
Med. 2:1041–1045. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang VE, Urisman A, Albacker L, Ali S,
Miller V, Aggarwal R and Jablons D: Checkpoint inhibitor is active
against large cell neuroendocrine carcinoma with high tumor
mutation burden. J Immunother Cancer. 5:752017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weber MM and Fottner C: Immune checkpoint
inhibitors in the treatment of patients with neuroendocrine
neoplasia. Oncol Res Treat. 41:306–312. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ferrara MG, Stefani A, Simbolo M, Pilotto
S, Martini M, Lococo F, Vita E, Chiappetta M, Cancellieri A,
D'Argento E, et al: Large Cell Neuro-Endocrine carcinoma of the
lung: Current treatment options and potential future opportunities.
Front Oncol. 11:6502932021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fan Y, Ma K, Wang C, Ning J, Hu Y, Dong D,
Dong X, Geng Q, Li E and Wu Y: Prognostic value of PD-L1 and PD-1
expression in pulmonary neuroendocrine tumors. Onco Targets Ther.
9:6075–6082. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim HS, Lee JH, Nam SJ, Ock CY, Moon JW,
Yoo CW, Lee GK and Han JY: Association of PD-L1 Expression with
Tumor-Infiltrating immune cells and mutation burden in high-grade
neuroendocrine carcinoma of the lung. J Thorac Oncol. 13:636–648.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tsuruoka K, Horinouchi H, Goto Y, Kanda S,
Fujiwara Y, Nokihara H, Yamamoto N, Asakura K, Nakagawa K, Sakurai
H, et al: PD-L1 expression in neuroendocrine tumors of the lung.
Lung Cancer. 108:115–120. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Karim NA, Sendilnathan A, Eldessouki I,
Orr-Asman MA, Xie C, Wang J and Elnakat H: PS06.06 immune
checkpoint markers in lung large cell neuroendocrine carcinomas
(L-LCNEC). J Thoracic Oncol. 12:1583–S1584. 2017. View Article : Google Scholar
|
|
46
|
Chauhan A, Arnold SM, Kolesar J, Thomas
HE, Evers M and Anthony L: Immune checkpoint inhibitors in large
cell neuroendocrine carcinoma: Current status. Oncotarget.
9:14738–14740. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Levra MG, Mazières J, Valette CA, Molinier
O, Planchard D, Frappat V, Ferrer L, Toffart AC and Moro-Sibilot D:
P1.07-012 efficacy of immune checkpoint inhibitors in large cell
neuroendocrine lung cancer: Results from a french retrospective
cohort. J Thoracic Oncol. S12 (Suppl):S702–S703. 2017. View Article : Google Scholar
|
|
48
|
Agar C, Geier M, Leveiller G, Lamy R,
Bizec JL, Tiercin M, Bernier C, Robinet G, Lena H, Ricordel C, et
al: Brief report on the efficacy of nivolumab in patients with
previously treated advanced Large-Cell neuroendocrine cancer of the
lung. JTO Clin Res Rep. 2:1001292021.PubMed/NCBI
|
|
49
|
Zhang X, Sun Y, Miao Y and Xu S: Immune
checkpoint inhibitor therapy achieved complete response for
drug-sensitive EGFR/ALK mutation-negative metastatic pulmonary
large-cell neuroendocrine carcinoma with high tumor mutation
burden: A case report. Onco Targets Ther. 13:8245–8250. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Takimoto Sato M, Ikezawa Y, Sato M, Suzuki
A and Kawai Y: Large cell neuroendocrine carcinoma of the lung that
responded to nivolumab: A case report. Mol Clin Oncol. 13:43–47.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sherman S, Rotem O, Shochat T, Zer A,
Moore A and Dudnik E: Efficacy of immune check-point inhibitors
(ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung
Cancer. 143:40–46. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Komiya T, Ravindra N and Powell E: Role of
immunotherapy in stage IV large cell neuroendocrine carcinoma of
the lung. Asian Pac J Cancer Prev. 22:365–370. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Barroso-Sousa R, Barry WT, Garrido-Castro
AC, Hodi FS, Min L, Krop IE and Tolaney SM: Incidence of endocrine
dysfunction following the use of different immune checkpoint
inhibitor regimens: A systematic review and meta-analysis. JAMA
Oncol. 4:173–182. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lee H, Hodi FS, Giobbie-Hurder A, Ott PA,
Buchbinder EI, Haq R, Tolaney S, Barroso-Sousa R, Zhang K, Donahue
H, et al: Characterization of thyroid disorders in patients
receiving immune checkpoint inhibition therapy. Cancer Immunol Res.
5:1133–1140. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhan L, Feng HF, Liu HQ, Guo LT, Chen C,
Yao XL and Sun SR: Immune Checkpoint Inhibitors-Related thyroid
dysfunction: Epidemiology, clinical presentation, possible
pathogenesis, and management. Front Endocrinol (Lausanne).
12:6498632021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang Y, Wang X, Cheng L and Zhang G:
Correlation analysis between thyroid function abnormality and
efficacy in patients with advanced Non-small cell lung cancer after
immunotherapy. Zhongguo Fei Ai Za Zhi. 26:369–376. 2023.(In
Chinese). PubMed/NCBI
|
